Louisiana State Employees Retirement System Buys Shares of 10,900 Catalent, Inc. (NYSE:CTLT)

Louisiana State Employees Retirement System purchased a new stake in Catalent, Inc. (NYSE:CTLT) during the 4th quarter, Holdings Channel reports. The firm purchased 10,900 shares of the company’s stock, valued at approximately $490,000.

A number of other hedge funds also recently made changes to their positions in CTLT. Gladius Capital Management LP acquired a new stake in Catalent in the 3rd quarter valued at approximately $28,000. Exchange Traded Concepts LLC bought a new position in shares of Catalent in the third quarter worth $31,000. Cary Street Partners Investment Advisory LLC increased its holdings in shares of Catalent by 1,162.3% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after purchasing an additional 709 shares during the period. PFG Private Wealth Management LLC bought a new stake in shares of Catalent during the third quarter valued at about $155,000. Finally, V Square Quantitative Management LLC acquired a new stake in Catalent in the third quarter worth about $181,000.

Catalent Trading Up 0.7 %

Shares of CTLT stock opened at $56.30 on Tuesday. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48. The firm has a fifty day moving average of $56.65 and a 200-day moving average of $48.78. Catalent, Inc. has a 52-week low of $31.45 and a 52-week high of $60.20. The stock has a market cap of $10.19 billion, a price-to-earnings ratio of -8.28, a P/E/G ratio of 6.03 and a beta of 1.20.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The business had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the business earned $0.62 EPS. The firm’s revenue for the quarter was down 10.2% on a year-over-year basis. On average, equities research analysts forecast that Catalent, Inc. will post 0.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CTLT has been the topic of several research analyst reports. Stephens reissued an “equal weight” rating and set a $63.50 target price on shares of Catalent in a research note on Thursday, April 4th. Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 target price on shares of Catalent in a report on Tuesday, February 20th. UBS Group restated a “neutral” rating and issued a $63.50 target price (up from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. StockNews.com initiated coverage on Catalent in a research report on Saturday. They set a “sell” rating on the stock. Finally, Barclays raised their target price on Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research note on Thursday, January 25th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Catalent currently has an average rating of “Hold” and a consensus price target of $52.46.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.